Intellia Therapeutics, Inc.
NTLA
$12.35
$0.151.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 15.83% | 25.69% | 25.34% | 31.11% | -6.42% |
| Total Depreciation and Amortization | -11.85% | 134.41% | 89.26% | -4.81% | -0.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.14% | -48.87% | -60.65% | -66.36% | 55.01% |
| Change in Net Operating Assets | 36.78% | -75.78% | -55.65% | -167.08% | -97.75% |
| Cash from Operations | 21.21% | 18.67% | 9.36% | -71.21% | -23.43% |
| Capital Expenditure | 89.25% | 87.16% | 97.73% | 76.38% | 70.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.16% | -81.87% | 88.93% | 562.29% | 1,030.76% |
| Cash from Investing | -29.70% | -81.83% | 90.39% | 541.96% | 1,498.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -14.67% | 39.74% | -64.48% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -14.67% | 39.74% | -64.48% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.01% | -157.91% | 459.45% | 153.34% | 0.30% |